Oxygen acquires cardio drug in $5M deal; NIH backs personalized med research with $29M Scripps grant;

@FierceBiotech: New feature: The top 10 biotech IPOs of 2013. Special report | Follow @FierceBiotech

@JohnCFierce: Problem with Lilly: even if they get new diabetes drugs approved--everyone is piling into the same niches. More from Bloomberg | Follow @JohnCFierce

@DamianFierce: Ariad's Iclusig agony has put a hold on its planned move to Cambridge's biotech hotbed. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: This week's issue of FierceBiotech Research is out. Check it out | Follow @EmilyMFierce

> Shares of Oxygen Biotherapeutics ($OXBT) spiked on the news that the company had acquired an experimental cardiovascular drug in exchange for about $5 million in stock. Oxygen acquired the drug from Phyxius. Story

> The NIH is providing a $29 million grant to Scripps Translational Science Institute to foster its work on personalized medicines. Story

Medical Device News

@FierceMedDev: Siemens skirts whistleblower suit over alleged Chinese kickbacks. News | Follow @FierceMedDev

> Thermo Fisher soars on diagnostics as blockbuster Life deal awaits. Story

> Illumina dazzles with Q3 diagnostics expansion and revenue growth. Report

> Myriad sues BioReference Laboratories alleging BRCA cancer test patent violation. Item

> Monteris bags $13M for laser neurosurgery tech. News

Pharma News

@FiercePharma: Tuesday's top news: Astellas + Medivation prostate-cancer prodigy Xtandi shines in pre-chemo. Article | Follow @FiercePharma

@EricPFierce: Amarin cuts 50% of its staff after FDA panel vote leaves Vascepa extension high and dry. News | Follow @EricPFierce

@CarlyHFierce: Reckitt Benckiser weighs pharma-unit sale as Suboxone slumps. More | Follow @CarlyHFierce

> Lilly diabetes drugs, price hikes fuel 6% sales boost. News

> GlaxoSmithKline bribery probe takes 61% bite out of China sales. More

> Amgen earnings jump amid Onyx buyout, Asia deal. Story

Drug Delivery News

@MichaelGFierce: New method allows first-ever delivery of highly toxic cancer drug. More | Follow @MichaelGFierce

> Molecular 'grenades' from GenSpera reel in PhI liver cancer success. Story

> Arcturus rakes in $5M to back RNAi tech, nanoparticle delivery. Article

> Study: Heated chemo-delivering nanoparticles kill 95% of ovarian cancer cells. Report

> Implantable, light-sensitive hydrogel could help treat diabetes. Item

Diagnostics News

@MarkHFierce: The top med tech VC investments of Q3 are all late-stage companies. Click for all the juicy details. FierceMedicalDevices feature | Follow @MarkHFierce

> Myriad targets 3rd company with BRCA cancer test lawsuit. News

> King's College London team make strides toward rapid sepsis test. More

> QuantuMDx gets $1.6M government grant for superfast, portable TB test. Story

> Precipio grabs $1.7M to grow cancer Dx services business with Yale connection. Article

> Roche to close 454 Life Sciences as it reduces gene sequencing focus. Report

And Finally… Researchers at Boston University say that testosterone therapy could reduce the risk of cardiovascular disease for men. Release

Suggested Articles

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.